Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > KOL Webinar Advert for Nov 14

<< Previous

Bullboard Posts

Next >>

Post by westcoast1000on Oct 25, 2022 11:07am

211 Views

Post# 35046574

KOL Webinar Advert for Nov 14

KOL Webinar on Pancreatic Cancer and Interim Results from the Phase 1/2 GOBLET Study Being Presented at the SITC 37^th Annual Meeting

Monday, November 14, 2022 | 10:00 AM ET

Hosted by Oncolytics Biotech Inc

(NASDAQ: ONCY, TSX: ONC)

Join us for a virtual key opinion leader (KOL) event with Oncolytics Biotech, featuring Dirk Arnold, MD, PhD (Asklepios Tumorzentrum Hamburg), Andrea Bullock, MD, MPH (Beth Israel Deaconess Medical Center) and Thomas Seufferlein, MD, PhD (Ulm University, Germany).

During the event, the KOLs and members of the Oncolytics management team will discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as interim results from the Phase 1/2 GOBLET study’s pancreatic cancer cohort being presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37^th Annual Meeting.

A live question and answer session will follow the formal presentations.

____

The bios of the three featured speakers are included. They are impressive and very well connected.

I got this advert through email this morning.

All the best to the longs.